Download PDF
CC BY-NC-ND 4.0 · World J Nucl Med 2020; 19(03): 273-276
DOI: 10.4103/wjnm.WJNM_49_19
Case Report

Cutaneous malignant melanoma with rarest combination of prostatic and splenic metastases on fluorodeoxyglucose (FDG) positron emission tomography—computed tomography scan

Digish Shah
Department of Nuclear Medicine and PET-CT, HCG Cancer Hospital, Department of Radiology, HCG Cancer Centre, Ahmedabad, Gujarat, India
,
Prakash Odedara
Department of Nuclear Medicine and PET-CT, HCG Cancer Hospital, Department of Radiology, HCG Cancer Centre, Ahmedabad, Gujarat, India
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Cutaneous malignant melanoma (MM) metastases to prostate and spleen are very rarely experienced in clinical setting. As per our knowledge, coexistence of prostate and splenic metastatic MM is not reported worldwide. We are presenting a case of 70-year-old male patients with biopsy and clinically proven case of multifocal cutaneous malignant melanomatous lesions having multiple metastatic lymph nodes and systemic metastases, including prostate and spleen. This is the first case reported worldwide having a combination of prostate and splenic metastases.

Keywords

Fluorodeoxyglucose (FDG) - malignant melanoma - positron emission tomography-computed tomography - prostatic-splenic metastasis

Financial support and sponsorship

Nil.




Publication History

Received: 25 June 2019

Accepted: 25 July 2019

Article published online:
19 April 2022

© 2020. Sociedade Brasileira de Neurocirurgia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Anand S, Verma R, Vaja C, Bade R, Shah A, Gaikwad K. Metastatic malignant melanoma: A case study. Int J Sci Stud 2016;4:188-90.
  • 2 Showalter SL, Hager E, Yeo CJ. Metastatic Disease to the Pancreas and Spleen. Semin oncol 2008;35:160-171.
  • 3 Belhocine TZ, Scott AM, Even-Sapir E, Urbain JL, Essner R. Role of nuclear medicine in the management of cutaneous malignant melanoma. J Nucl Med 2006;47:957-67.
  • 4 Krug B, Crott R, Lonneux M, Baurain JF, Pirson AS, Vander Borght T. Role of PET in the initial staging of cutaneous malignant melanoma: Systematic review. Radiology 2008;249:836-44.
  • 5 Bates AW, Baithun SI. Secondary solid neoplasms of the prostate: A clinico-pathological series of 51 cases. Virchows Arch 2002;440:392-6.
  • 6 Tosev G, Kuru TH, Huber J, Freier G, Bergmann F, Hassel JC, et al. Primary melanoma of the prostate: Case report and review of the literature. BMC Urol 2015;15:68.
  • 7 Clark WH Jr., Ainsworth AM, Bernardino EA, Yang CH, Mihm CM Jr., Reed RJ. The developmental biology of primary human malignant melanomas. Semin Oncol 1975;2:83-103.
  • 8 Stein BS, Kendall AR. Ma lignant melanoma of the genitourinary tract. J Urol 1984;132:859-68.
  • 9 Dasgupta T, Brasfield R. Metastatic melanoma. A clinicopathological study. Cancer 1964;17:1323-39.
  • 10 Giovagnoni A, Giorgi C, Goteri G. Tumours of the spleen. Cancer Imaging 2005;5:73-7.
  • 11 Lam KY, Tang V. Metastatic tumors to the spleen: A 25-year clinicopathologic study. Arch Pathol Lab Med 2000;124:526-30.
  • 12 Trindade MM, Blaya R, Trindade EN. Melanoma metastasis to the spleen: Laparoscopic approach. J Min Access Surg 2009;5:17-9.